blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3038656

EP3038656 - COMPOUND OF GLYCOSAMINOGLYCAN, PREPARATION METHOD AND USE THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  24.06.2022
Database last updated on 01.04.2026
FormerThe patent has been granted
Status updated on  16.07.2021
FormerGrant of patent is intended
Status updated on  30.06.2021
FormerExamination is in progress
Status updated on  21.05.2021
FormerGrant of patent is intended
Status updated on  11.04.2021
FormerExamination is in progress
Status updated on  28.09.2018
Most recent event   Tooltip06.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 09.10.2024  [2024/41]
Applicant(s)For all designated states
Holy Stone Biotech Co., Ltd.
Henderson Business Centre Unit 32/33
Ivy Road
Norwich, Norfolk NR5 8BF / GB
[2021/33]
Former [2016/27]For all designated states
Holy Stone Biotech Co., Ltd.
Henderson Business Centre Unit 32/33
Ivy Road
Norwich, Norfolk NR5 8BF / GB
Inventor(s)01 / LIN, Hua-Yang
4F., No. 88, Sec. 1
Neihu Rd.
Neihu Dist.
Taipei 11493 / TW
 [2021/33]
Former [2016/27]01 / LIN, Hua-Yang
4F. No. 88 Sec. 1
Neihu Rd.
Neihu Dist.
Taipei 11493 / TW
Representative(s)Valenza, Silvia, et al
Notarbartolo & Gervasi S.p.A.
Viale Achille Papa, 30
20149 Milano / IT
[2021/33]
Former [2016/27]Gervasi, Gemma, et al
Notarbartolo & Gervasi S.p.A.
Corso di Porta Vittoria 9
20122 Milano / IT
Application number, filing date14746964.727.06.2014
[2016/27]
WO2014EP63720
Priority number, dateUS201361871352P29.08.2013         Original published format: US 201361871352 P
US20141430897219.06.2014         Original published format: US201414308972
[2016/27]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015028172
Date:05.03.2015
Language:EN
[2015/09]
Type: A1 Application with search report 
No.:EP3038656
Date:06.07.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 05.03.2015 takes the place of the publication of the European patent application.
[2016/27]
Type: B1 Patent specification 
No.:EP3038656
Date:18.08.2021
Language:EN
[2021/33]
Search report(s)International search report - published on:EP05.03.2015
(Supplementary) European search report - dispatched on:EP08.10.2018
ClassificationIPC:A61K47/61, A61P35/00, A61P35/02, A61K31/145, A61K31/18, A61K31/415, A61K31/445, A61K31/454, A61K31/573, A61K31/635, A61K31/7068, A61K31/728
[2021/17]
CPC:
A61K31/728 (EP,EA,US); A61K47/61 (EP,EA,KR,US); A61P35/00 (EP,EA);
A61K31/145 (EP,EA,KR,US); A61K31/18 (EP,US); A61K31/415 (EP,EA,KR,US);
A61K31/445 (EP,EA,US); A61K31/454 (EP,EA,KR,US); A61K31/573 (EP,EA,US);
A61K31/635 (EP,US); A61K31/7068 (EP,EA,KR,US); A61K31/726 (EA,KR);
A61K47/549 (EA,KR); A61P1/04 (EP); A61P1/16 (EP);
A61P1/18 (EP); A61P11/00 (EP); A61P13/02 (EP);
A61P13/08 (EP); A61P13/12 (EP); A61P15/00 (EP);
A61P19/02 (EP); A61P29/00 (EP); A61P31/00 (EP);
A61P35/02 (EP); A61P35/04 (US); A61P37/00 (EP);
A61P37/06 (EP); A61P37/08 (EP); A61P43/00 (EP);
A61P7/00 (EP) (-)
Former IPC [2018/44]A61K47/61, A61P35/00
Former IPC [2016/27]A61K47/48, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/27]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:VERBINDUNG AUS GLUCOSAMINOGLUCAN, HERSTELLUNGSVERFAHREN UND VERWENDUNG DAVON[2016/27]
English:COMPOUND OF GLYCOSAMINOGLYCAN, PREPARATION METHOD AND USE THEREOF[2016/27]
French:COMPOSÉ DE GLYCOSAMINOGLYCANE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION[2016/27]
Entry into regional phase25.03.2016National basic fee paid 
25.03.2016Designation fee(s) paid 
25.03.2016Examination fee paid 
Examination procedure25.03.2016Amendment by applicant (claims and/or description)
25.03.2016Examination requested  [2016/27]
08.10.2018Despatch of a communication from the examining division to which search results under Rule 164(2) EPC are annexed (Time limit: M04) [2018/44]
08.10.2018Despatch of a communication from the examining division (Time limit: M04)
11.02.2019Reply to a communication from the examining division
23.04.2020Despatch of a communication from the examining division (Time limit: M04)
05.06.2020Reply to a communication from the examining division
12.04.2021Communication of intention to grant the patent
20.05.2021Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
24.05.2021Fee for grant paid
24.05.2021Fee for publishing/printing paid
07.07.2021Communication of intention to grant the patent
12.07.2021Receipt of the translation of the claim(s)
Opposition(s)19.05.2022No opposition filed within time limit [2022/30]
Fees paidRenewal fee
10.06.2016Renewal fee patent year 03
16.06.2017Renewal fee patent year 04
11.06.2018Renewal fee patent year 05
10.06.2019Renewal fee patent year 06
31.03.2020Renewal fee patent year 07
08.06.2021Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL18.08.2021
CY18.08.2021
EE18.08.2021
HR18.08.2021
LV18.08.2021
MC18.08.2021
MK18.08.2021
MT18.08.2021
RO18.08.2021
RS18.08.2021
SI18.08.2021
SM18.08.2021
BG18.11.2021
IS18.12.2021
[2024/41]
Former [2024/22]AL18.08.2021
CY18.08.2021
EE18.08.2021
HR18.08.2021
LV18.08.2021
MC18.08.2021
MK18.08.2021
RO18.08.2021
RS18.08.2021
SI18.08.2021
SM18.08.2021
BG18.11.2021
IS18.12.2021
Former [2024/20]AL18.08.2021
CY18.08.2021
EE18.08.2021
HR18.08.2021
LV18.08.2021
MC18.08.2021
RO18.08.2021
RS18.08.2021
SI18.08.2021
SM18.08.2021
BG18.11.2021
IS18.12.2021
Former [2023/08]AL18.08.2021
EE18.08.2021
HR18.08.2021
LV18.08.2021
MC18.08.2021
RO18.08.2021
RS18.08.2021
SI18.08.2021
SM18.08.2021
BG18.11.2021
IS18.12.2021
Former [2022/36]AL18.08.2021
EE18.08.2021
HR18.08.2021
LV18.08.2021
RO18.08.2021
RS18.08.2021
SI18.08.2021
SM18.08.2021
BG18.11.2021
IS18.12.2021
Former [2022/29]AL18.08.2021
EE18.08.2021
HR18.08.2021
LV18.08.2021
RO18.08.2021
RS18.08.2021
SM18.08.2021
BG18.11.2021
IS18.12.2021
Former [2022/26]EE18.08.2021
HR18.08.2021
LV18.08.2021
RO18.08.2021
RS18.08.2021
SM18.08.2021
BG18.11.2021
IS18.12.2021
Former [2022/24]EE18.08.2021
HR18.08.2021
LV18.08.2021
RO18.08.2021
RS18.08.2021
BG18.11.2021
IS18.12.2021
Former [2022/10]HR18.08.2021
LV18.08.2021
RS18.08.2021
BG18.11.2021
IS18.12.2021
Former [2022/09]RS18.08.2021
BG18.11.2021
Cited inInternational search[A] WO2008134528  (UNIV TEXAS et al.)
 [A]   CHIARA DI MEO ET AL: "Hyaluronan as Carrier of Carboranes for Tumor Targeting in Boron Neutron Capture Therapy", BIOMACROMOLECULES, vol. 8, no. 2, 1 February 2007 (2007-02-01), pages 552 - 559, XP055142431, ISSN: 1525-7797, DOI: 10.1021/bm0607426

DOI:   http://dx.doi.org/10.1021/bm0607426
 [A]   ROSATO A ET AL: "HYTAD1-p20: A new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer", UROLOGIC ONCOLOGY, ELSEVIER, NEW YORK, NY, US, vol. 24, no. 3, 1 May 2006 (2006-05-01), pages 207 - 215, XP028071920, ISSN: 1078-1439, [retrieved on 20060501], DOI: 10.1016/J.UROLONC.2005.08.020

DOI:   http://dx.doi.org/10.1016/j.urolonc.2005.08.020
 [A]   SERAFINO A ET AL: "CD44-targeting for antitumor drug delivery: A new SN-38-hyaluronan bioconjugate for locoregional treatment of peritoneal carcinomatosis", CURRENT CANCER DRUG TARGETS 2011 BENTHAM SCIENCE PUBLISHERS B.V. NLD, vol. 11, no. 5, June 2011 (2011-06-01), pages 572 - 585, XP008172354, ISSN: 1568-0096

DOI:   http://dx.doi.org/10.2174/156800911795655976
 [A]   W M LIU ET AL: "Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs)", BRITISH JOURNAL OF CANCER, vol. 101, no. 5, 28 July 2009 (2009-07-28), pages 803 - 812, XP055142773, ISSN: 0007-0920, DOI: 10.1038/sj.bjc.6605206

DOI:   http://dx.doi.org/10.1038/sj.bjc.6605206
 [AD]   KOTLA VENUMADHAV ET AL: "Mechanism of action of lenalidomide in hematological malignancies", JOURNAL OF HEMATOLOGY & ONCOLOGY, BIOMED CENTRAL LTD, LONDON UK, vol. 2, no. 1, 12 August 2009 (2009-08-12), pages 36, XP021060855, ISSN: 1756-8722, DOI: 10.1186/1756-8722-2-36

DOI:   http://dx.doi.org/10.1186/1756-8722-2-36
ExaminationUS5733891
 WO2011130476
 EP1710257
 CN101732728
by applicantWO9409811
 WO9945942
 US8192744
   GUNTHERT ET AL.: "A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells", CELL, vol. 65, no. 1, 5 December 1990 (1990-12-05), pages 13 - 24, XP023913169, DOI: doi:10.1016/0092-8674(91)90403-L

DOI:   http://dx.doi.org/10.1016/0092-8674(91)90403-L
   F REIHANI-SABET ET AL.: "Effects of Inflammation and H. pylori Infection on Expression of CD44 Variant Exons in Gastric Tissue", JOURNAL OF SCIENCES, vol. 14, 2003, pages 11 - 16
   ELIAZ, R. E. ET AL.: "Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells", CANCER RES., vol. 61, no. 6, 2004, pages 2592 - 601, XP001030696
   SANDLER RS. ET AL.: "A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer", NEW ENGLAND J. MED., vol. 348, 2003, pages 883 - 890
   YAMAZAKI R. ET AL.: "Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells", FEBS LETT., vol. 531, no. 2, 2002, pages 278 - 84, XP004391645, DOI: doi:10.1016/S0014-5793(02)03535-4

DOI:   http://dx.doi.org/10.1016/S0014-5793(02)03535-4
   DANNENBERG AJ. ET AL.: "Targeting cyclooxygenase-2 in human neoplasia: rationale and promise", CANCER CELL, vol. 4, no. 6, 2003, pages 431 - 6
   ALANE T.KOKI ET AL.: "Celecoxib: A Specific COX-2 Inhibitor With Anticancer Properties", CANCER CONTROL, vol. 9, no. 2, 2002, pages 28 - 35, XP009074259
   ZHANG YJ. ET AL.: "mTOR signaling is involved in indomethacin and Nimesulide suppression of colorectal cancer cell growth via a COX-2 independent pathway", ANN SURG ONCOL., vol. 18, no. 2, 2011, pages 580 - 8, XP019879260, DOI: doi:10.1245/s10434-010-1268-9

DOI:   http://dx.doi.org/10.1245/s10434-010-1268-9
   V. KOTLA ET AL.: "Mechanism of action of Lenalidomide in hematological malignancies", JOURNAL OF HEMATOLOGY AND ONCOLOGY, vol. 2, 2009, pages 36, XP021060855, DOI: doi:10.1186/1756-8722-2-36

DOI:   http://dx.doi.org/10.1186/1756-8722-2-36
   J. SHESKIN: "The treatment of lepra reaction in lepromatous leprosy", INTERNATIONAL JOURNAL OF DERMATOLOGY, vol. 6, 1980, pages 318 - 322
   E. ATRA; E. . SATO: "Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide", CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, vol. 11, no. 5, 1993, pages 487 - 93
   VENUMADHAV KOTLA ET AL.: "Mechanism of action of Lenalidomide in hematological malignancies", JOURNAL OF HEMATOLOGY & ONCOLOGY, vol. 2, 2009, pages 36, XP021060855, DOI: doi:10.1186/1756-8722-2-36

DOI:   http://dx.doi.org/10.1186/1756-8722-2-36
   VERHELLE D. ET AL.: "Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells", CANCER RES., vol. 67, no. 2, 2007, pages 746 - 55, XP055422983, DOI: doi:10.1158/0008-5472.CAN-06-2317

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-06-2317
   GUPTA D. ET AL.: "Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications", LEUKEMIA, vol. 15, no. 12, 2001, pages 1950 - 61
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.